FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3035057179> ?p ?o ?g. }

• W3035057179 abstract "Abstract Background A model that can predict treatment response for a patient with specific baseline characteristics would help decision-making in personalized medicine. The aim of the study is to develop such a model in the treatment of rheumatoid arthritis (RA) patients who receive certolizumab (CTZ) plus methotrexate (MTX) therapy, using individual participant data meta-analysis (IPD-MA). Methods We will search Cochrane CENTRAL, PubMed, and Scopus as well as clinical trial registries, drug regulatory agency reports, and the pharmaceutical company websites from their inception onwards to obtain randomized controlled trials (RCTs) investigating CTZ plus MTX compared with MTX alone in treating RA. We will request the individual-level data of these trials from an independent platform ( http://vivli.org ). The primary outcome is efficacy defined as achieving either remission (based on ACR-EULAR Boolean or index-based remission definition) or low disease activity (based on either of the validated composite disease activity measures). The secondary outcomes include ACR50 (50% improvement based on ACR core set variables) and adverse events. We will use a two-stage approach to develop the prediction model. First, we will construct a risk model for the outcomes via logistic regression to estimate the baseline risk scores. We will include baseline demographic, clinical, and biochemical features as covariates for this model. Next, we will develop a meta-regression model for treatment effects, in which the stage 1 risk score will be used both as a prognostic factor and as an effect modifier. We will calculate the probability of having the outcome for a new patient based on the model, which will allow estimation of the absolute and relative treatment effect. We will use R for our analyses, except for the second stage which will be performed in a Bayesian setting using . Discussion This is a study protocol for developing a model to predict treatment response for RA patients receiving CTZ plus MTX in comparison with MTX alone, using a two-stage approach based on IPD-MA. The study will use a new modeling approach, which aims at retaining the statistical power. The model may help clinicians individualize treatment for particular patients. Systematic review registration PROSPERO registration number pending (ID#157595)." @default.
• W3035057179 created "2020-06-19" @default.
• W3035057179 creator A5003292761 @default.
• W3035057179 creator A5019602773 @default.
• W3035057179 creator A5068265721 @default.
• W3035057179 creator A5071914470 @default.
• W3035057179 creator A5085050194 @default.
• W3035057179 creator A5088217633 @default.
• W3035057179 date "2020-06-12" @default.
• W3035057179 modified "2023-09-24" @default.
• W3035057179 title "Predicting the treatment response of certolizumab for individual adult patients with rheumatoid arthritis: protocol for an individual participant data meta-analysis" @default.
• W3035057179 cites W1588610010 @default.
• W3035057179 cites W1792005172 @default.
• W3035057179 cites W1841651683 @default.
• W3035057179 cites W1994742944 @default.
• W3035057179 cites W2037659027 @default.
• W3035057179 cites W2049192772 @default.
• W3035057179 cites W2050118439 @default.
• W3035057179 cites W2099559598 @default.
• W3035057179 cites W2104669609 @default.
• W3035057179 cites W2105037937 @default.
• W3035057179 cites W2107053960 @default.
• W3035057179 cites W2120393706 @default.
• W3035057179 cites W2120959053 @default.
• W3035057179 cites W2135046866 @default.
• W3035057179 cites W2136215457 @default.
• W3035057179 cites W2145517217 @default.
• W3035057179 cites W2146404132 @default.
• W3035057179 cites W2152348310 @default.
• W3035057179 cites W2156831284 @default.
• W3035057179 cites W2159106700 @default.
• W3035057179 cites W2161374186 @default.
• W3035057179 cites W2162491525 @default.
• W3035057179 cites W2167702473 @default.
• W3035057179 cites W2337058918 @default.
• W3035057179 cites W2410591240 @default.
• W3035057179 cites W2444170710 @default.
• W3035057179 cites W2517073520 @default.
• W3035057179 cites W2533466707 @default.
• W3035057179 cites W2600354684 @default.
• W3035057179 cites W2725127520 @default.
• W3035057179 cites W2771335117 @default.
• W3035057179 cites W2799497182 @default.
• W3035057179 cites W2805681256 @default.
• W3035057179 cites W2898559532 @default.
• W3035057179 cites W2902368204 @default.
• W3035057179 cites W2904040183 @default.
• W3035057179 cites W2921861522 @default.
• W3035057179 cites W2943094354 @default.
• W3035057179 cites W2970684805 @default.
• W3035057179 cites W2971880487 @default.
• W3035057179 cites W4295125684 @default.
• W3035057179 doi "https://doi.org/10.1186/s13643-020-01401-x" @default.
• W3035057179 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7477831" @default.
• W3035057179 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32532307" @default.
• W3035057179 hasPublicationYear "2020" @default.
• W3035057179 type Work @default.
• W3035057179 sameAs 3035057179 @default.
• W3035057179 citedByCount "3" @default.
• W3035057179 countsByYear W30350571792021 @default.
• W3035057179 countsByYear W30350571792023 @default.
• W3035057179 crossrefType "journal-article" @default.
• W3035057179 hasAuthorship W3035057179A5003292761 @default.
• W3035057179 hasAuthorship W3035057179A5019602773 @default.
• W3035057179 hasAuthorship W3035057179A5068265721 @default.
• W3035057179 hasAuthorship W3035057179A5071914470 @default.
• W3035057179 hasAuthorship W3035057179A5085050194 @default.
• W3035057179 hasAuthorship W3035057179A5088217633 @default.
• W3035057179 hasBestOaLocation W30350571791 @default.
• W3035057179 hasConcept C119043178 @default.
• W3035057179 hasConcept C119857082 @default.
• W3035057179 hasConcept C126322002 @default.
• W3035057179 hasConcept C151956035 @default.
• W3035057179 hasConcept C168563851 @default.
• W3035057179 hasConcept C1862650 @default.
• W3035057179 hasConcept C197934379 @default.
• W3035057179 hasConcept C2777575956 @default.
• W3035057179 hasConcept C41008148 @default.
• W3035057179 hasConcept C535046627 @default.
• W3035057179 hasConcept C71924100 @default.
• W3035057179 hasConcept C95190672 @default.
• W3035057179 hasConceptScore W3035057179C119043178 @default.
• W3035057179 hasConceptScore W3035057179C119857082 @default.
• W3035057179 hasConceptScore W3035057179C126322002 @default.
• W3035057179 hasConceptScore W3035057179C151956035 @default.
• W3035057179 hasConceptScore W3035057179C168563851 @default.
• W3035057179 hasConceptScore W3035057179C1862650 @default.
• W3035057179 hasConceptScore W3035057179C197934379 @default.
• W3035057179 hasConceptScore W3035057179C2777575956 @default.
• W3035057179 hasConceptScore W3035057179C41008148 @default.
• W3035057179 hasConceptScore W3035057179C535046627 @default.
• W3035057179 hasConceptScore W3035057179C71924100 @default.
• W3035057179 hasConceptScore W3035057179C95190672 @default.
• W3035057179 hasIssue "1" @default.
• W3035057179 hasLocation W30350571791 @default.
• W3035057179 hasLocation W30350571792 @default.
• W3035057179 hasLocation W30350571793 @default.
• W3035057179 hasLocation W30350571794 @default.
• W3035057179 hasLocation W30350571795 @default.
• W3035057179 hasOpenAccess W3035057179 @default.

• next